Valuation: Viatris Inc.

Market Cap 20.22B 17.96B 16.76B 15.28B 28.82B 1,943B 29.09B 203B 78.61B 993B 75.9B 74.25B 3,188B P/E 2026 *
75.7x
P/E 2027 * 43.3x
Enterprise Value 32.17B 28.58B 26.67B 24.31B 45.85B 3,092B 46.28B 323B 125B 1,581B 121B 118B 5,073B EV / Sales 2026 *
2.18x
EV / Sales 2027 * 2.05x
Free-Float
91.44%
Yield 2026 *
2.89%
Yield 2027 * 2.97%
1 day+1.81%
1 week+1.22%
Current month-2.76%
1 month+5.98%
3 months+7.53%
6 months+32.44%
Current year+47.20%
1 week 15.46
Extreme 15.456
16.14
1 month 13.93
Extreme 13.932
16.14
Current year 10.49
Extreme 10.49
16.14
1 year 8.4
Extreme 8.404
16.14
3 years 6.26
Extreme 6.262
16.14
5 years 6.26
Extreme 6.262
16.14
10 years 6.26
Extreme 6.262
16.14
Manager TitleAgeSince
Chief Executive Officer 63 01/04/2023
Director of Finance/CFO 59 08/05/2026
Chief Tech/Sci/R&D Officer - 15/12/2023
Director TitleAgeSince
Director/Board Member 78 16/11/2020
Director/Board Member 78 16/11/2020
Director/Board Member 62 16/11/2020
Change 5-day change 1-year change 3-year change Capi.($)
+1.81%+1.22% - - 20.22B
-0.61%-3.43%+36.07%+115.04% 1,019B
-1.02%-5.60%+35.72%+64.63% 617B
+1.11%-0.58%+12.36%+77.95% 464B
+0.34%-3.01%+61.79%+41.24% 356B
+1.13%-1.55%+21.32%+41.83% 333B
+0.99%-3.13%+11.15%+34.82% 267B
+0.29%-4.58%-6.33%+9.34% 244B
-1.04%-2.79%+35.30%+51.84% 218B
-1.87%-4.10%+28.44%+93.66% 179B
Average +0.13%-3.54%+26.20%+58.93% 410.8B
Weighted average by Cap. -0.08%-3.54%+29.18%+70.75%

Financials

2026 *2027 *
Net sales 14.79B 13.14B 12.26B 11.18B 21.08B 1,422B 21.28B 148B 57.51B 727B 55.53B 54.32B 2,333B 15.04B 13.36B 12.47B 11.37B 21.44B 1,446B 21.64B 151B 58.48B 739B 56.46B 55.23B 2,372B
Net income 142M 126M 117M 107M 202M 13.6B 204M 1.42B 550M 6.95B 531M 520M 22.32B 298M 265M 247M 226M 425M 28.69B 429M 2.99B 1.16B 14.67B 1.12B 1.1B 47.07B
Net Debt 11.95B 10.62B 9.91B 9.03B 17.04B 1,149B 17.19B 120B 46.47B 587B 44.87B 43.9B 1,885B 10.68B 9.49B 8.86B 8.08B 15.23B 1,027B 15.37B 107B 41.55B 525B 40.11B 39.24B 1,685B
Logo Viatris Inc.
Viatris Inc. is a global healthcare company. The Company markets branded and generic drugs, including complex drugs. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. Its Developed Markets segment comprises its operations primarily in North America and Europe. The Company's Greater China segment includes its operations in mainland China, Taiwan and Hong Kong. The Company's JANZ segment consists of its operations in Japan, Australia and New Zealand. Its Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies including in Asia, Africa, Eastern Europe, Latin America and the Middle East as well as the Company's ARV franchise. It produces medicines for patients across a broad range of major therapeutic areas. From cardiovascular health to oncology, it offers treatment options across more than 10 major therapeutic areas covering a variety of noncommunicable and infectious diseases.
Employees
30,000
Date Price Change Volume
02/10/26 €15.46 -1.63% 0
01/10/26 €15.71 -1.15% 0
30/09/26 €15.89 -0.95% 0
29/09/26 €16.05 +2.36% 0
28/09/26 €15.68 +2.66% 0
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
17.60USD
Average target price
19.40USD
Spread / Average Target
+10.23%

Quarterly revenue - Rate of surprise